For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated ...

ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced its financial results for the third quarter of 2024, alongside ...

A new study presents a customised treatment strategy using antisense oligonucleotides (ASOs) to target EGFR mutations in ...

Lung cancer is the top cause of cancer-related deaths globally, more prevalent in men, and ranks third among women. Both ...